Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Shares Acquired by Convergence Investment Partners LLC

Convergence Investment Partners LLC increased its holdings in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 24.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 208,009 shares of the company's stock after purchasing an additional 41,161 shares during the period. Convergence Investment Partners LLC owned 0.07% of Amneal Pharmaceuticals worth $1,647,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the business. Geode Capital Management LLC lifted its stake in shares of Amneal Pharmaceuticals by 11.1% in the 3rd quarter. Geode Capital Management LLC now owns 3,786,671 shares of the company's stock worth $31,511,000 after acquiring an additional 378,136 shares during the period. State Street Corp lifted its stake in shares of Amneal Pharmaceuticals by 3.8% in the 3rd quarter. State Street Corp now owns 3,514,721 shares of the company's stock worth $29,242,000 after acquiring an additional 127,753 shares during the period. Hennessy Advisors Inc. lifted its stake in shares of Amneal Pharmaceuticals by 6.8% in the 4th quarter. Hennessy Advisors Inc. now owns 1,670,600 shares of the company's stock worth $13,231,000 after acquiring an additional 106,600 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in shares of Amneal Pharmaceuticals by 16.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,404,883 shares of the company's stock worth $11,689,000 after acquiring an additional 202,863 shares during the period. Finally, JPMorgan Chase & Co. lifted its stake in shares of Amneal Pharmaceuticals by 149.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,297,094 shares of the company's stock worth $10,792,000 after acquiring an additional 777,568 shares during the period. Institutional investors and hedge funds own 31.82% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on AMRX shares. StockNews.com downgraded shares of Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Thursday, December 19th. Piper Sandler increased their price target on shares of Amneal Pharmaceuticals from $9.00 to $11.00 and gave the company an "overweight" rating in a report on Monday, November 11th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $10.00.

Insider Buying and Selling at Amneal Pharmaceuticals

In other Amneal Pharmaceuticals news, Director Gautam Patel sold 80,000 shares of the firm's stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $8.14, for a total transaction of $651,200.00. Following the completion of the transaction, the director now directly owns 1,888,886 shares in the company, valued at approximately $15,375,532.04. This trade represents a 4.06 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In the last three months, insiders sold 160,000 shares of company stock worth $1,292,000. 26.56% of the stock is owned by corporate insiders.

Amneal Pharmaceuticals Stock Performance

NASDAQ:AMRX traded down $0.04 during mid-day trading on Friday, hitting $7.83. 1,313,105 shares of the company's stock traded hands, compared to its average volume of 1,110,597. The firm's 50 day simple moving average is $8.04 and its 200 day simple moving average is $8.27. Amneal Pharmaceuticals, Inc. has a 1 year low of $5.01 and a 1 year high of $9.48. The company has a market cap of $2.43 billion, a PE ratio of -11.51 and a beta of 1.10.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.